Related Experiment Videos
[Epidemiological context: microbiological value of Synercid].
1Laboratoire Central de Microbiologie, Hôpital Edouard Herriot, Lyon.
Presse Medicale (Paris, France : 1983)
|October 18, 2001
Summary
Synercid, a combination antibiotic, effectively inhibits bacterial growth by targeting protein synthesis through synergistic binding to bacterial ribosomes. It demonstrates broad activity against Gram-positive cocci, including resistant strains.
Area of Science:
- Microbiology
- Pharmacology
Context:
- Synercid is a novel antibiotic formulation combining dafopristin (70%) and quinupristin (30%).
- It operates on the principle of molecular synergism to combat bacterial infections.
Purpose:
- To elucidate the mechanism of action and in vitro activity of Synercid.
- To investigate bacterial resistance mechanisms against Synercid.
Summary:
- Synercid functions by dafopristin binding to the 50S ribosomal subunit, enhancing quinupristin affinity, thereby blocking bacterial protein synthesis and growth.
- In vitro studies show Synercid is highly active against Gram-positive cocci, including methicillin-sensitive and resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Enterococcus faecium.
- Resistance mechanisms include ribosomal target modification, enzyme inactivation, and efflux, with a low prevalence observed in clinical studies.
Impact:
- Synercid provides a valuable therapeutic option against challenging Gram-positive bacterial infections.
- Understanding resistance mechanisms is crucial for optimizing the use of Synercid and developing future antimicrobial strategies.